This study reported that the ExoDxTM prostate test successfully stratified patients into low- and high-grade prostate cancer risk categories, assisting physicians in making informed decisions regarding the necessity of biopsies for patients with uncertain cancer risk based on prostate specific antigen results. Here, KLK3 is linked to prostate cancer.